Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea

NCT02446691 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02446691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
July 13, 2015
Completion date
December 28, 2017
Enrollment
128 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal